This article has Open Peer Review reports available.
Successful treatment of fusarium solani ecthyma gangrenosum in a patient affected by leukocyte adhesion deficiency type 1 with granulocytes transfusions
© Mellouli et al; licensee BioMed Central Ltd. 2010
Received: 29 April 2010
Accepted: 7 October 2010
Published: 7 October 2010
Ecthyma gangrenosum (EG) manifests as a skin lesion affecting patients suffering extreme neutropenia and is commonly associated with Pseudomonas aeruginosa in immunocompromised patients. Leukocyte adhesion deficiency I (LAD I) which count among primary immunodeficiency syndromes of the innate immunity, is an autosomal recessive disorder characterized in its severe phenotype by a complete defect in CD18 expression on neutrophils, delayed cord separation, chronic skin ulcers mainly due to recurrent bacterial and fungal infections, leucocytosis with high numbers of circulating neutrophils and an accumulation of abnormally low number of neutrophils at sites of infection.
We report at our knowledge the first case of a child affected by LAD-1, who experienced during her disease course a multi-bacterial and fungal EG lesion caused by fusarium solani. Despite targeted antibiotics and anti-fungi therapy, the lesion extended for as long as 18 months and only massive granulocytes pockets transfusions in association with G-CSF had the capacity to cure this lesion.
We propose that granulocytes pockets transfusions will be beneficial to heal EG especially in severely immunocompromised patients.
Leukocyte adhesion deficiency I (LAD I) is an autosomal recessive disorder characterized by defect in CD18 expression on neutrophils, leading to leucocytosis with high numbers of circulating neutrophils and an accumulation of abnormally low number of neutrophils at sites of infection. Recurrent bacterial and fungal infections count among clinical complications of such disorder . Nonetheless, ecthyma gangrenosum (EG) which represents a cutaneous infection mainly associated with pseudomonal sepsis in immunocompromised patient suffering extreme neutropenia [2, 3], was never reported in the setting of LAD I.
We report a case of a child affected by LAD-1, who experienced a fusarium solani EG lesion. The lesion extended for as long as 18 months and only massive granulocytes pockets transfusions in association with G-CSF had the capacity to cure this lesion.
A 9 years old girl affected by LAD-1 developed after a fall an abscess on her knee. Cultures taken from the lesion revealed a Pseudomonas aeruginosa infection. She was treated with amikacine 400 mg/day and imipenem 400 × 2 mg/day for three weeks and local disinfection. Lesion cultures performed one month later were negative. As all patients affected by such immunodeficiency, she was constantly under prophylactic treatment [25 mg/Kg/2 days (sulfamethoxazole + trimetoprime) and 10 mg/Kg/day Itraconazole].
Three months later, the patient was readmitted with 7 cm diameter erythematous and edematous lesion around necrotic center consistent with EG. The patient was apyretic and no pus was present. Laboratory findings were: peripheral WBC 23,000 mm3 (86% neutrophils); hemoglobin 8 g/dL. C-reactive protein was 106 mg/dL. Skin biopsies showed epidermal necrosis and ulceration with inflammatory granular cell infiltrates composed largely by lymphocytes, plasma cells, histiocytes, macrophages and rare eosinophiles. At that time, a necrotic vasculitis was confirmed but no bone lesion was found.
In front of this over a year persistent infection, we started transfusions of irradiated, phenotyped granulocytes pockets (3 pockets per week in median) along with G-CSF 5 μg/Kg/day; liposomal amphotericine B (Abelcet 2 mg/Kg/day), amphotericine B (0,3 mg/Kg/day up to 2 mg/Kg/day), flucytosine, and targeted antibiotics. Amphotericine B was stopped after 6 months and only granulocytes transfusions, G-CSF and Flucytosine were administered for the 2 latter months (Figure 1). After almost 5 months of such treatment cultures became negative, EG reduced progressively and then disappeared completely. Healing was complete but poorly formed as for patients suffering of such primary immunodeficiency.
EG is one of the most serious cutaneous infections which occurs frequently in patients with neutropenia and underlying malignancies [4, 5]. According to its pathogenesis, there are two main types of EG, with and without bacteremia. Skin lesions of the bacteremic type occur by hematological spread and blood cultures are positive, whereas in the better prognosis nonbacteremic form, lesions occur on the skin where organisms are inoculated . Even though most lesions are located in the gluteal and perineal regions , our patient had a knee lesion following a trauma. After a restricted skin location during months, there was a germs blood spread and bacteremia episodes that may be responsible of EG persistence in our patient. Moreover, lack of neutrophils migration to infectious sites because of LAD constitutes somewhat a delay of treatment and may explain secondary bacteremia as reported .
Pseudomonas aeruginosa was the first bacteria isolated and was almost always present  with fusarium solani in our patients' lesion (Figure 1). Less commonly, non-pseudomonal pathogens like Citrobacter freundii, E. coli, Aeromonas hydrophila, Stenotrophomonas maltophilia, Staphylococcus aureus, and non-bacteremic states have been associated with EG . Only one case of fusarium solani EG about a child affected by acute leukemia relapse was published . Evolution was favorable and the child was completely cured when he recovered from aplasia. The fundamental difference between our case and those reported is the permanent condition of granulocyte inefficiency for our patient. Whereas for patients not affected by LAD I, treatment result can't be completely dissociated of granulocyte recovery. While neutropenia represent [2, 3] the major predisposing factor for EG, the failure of neutophils to reach lesion location due to adhesion molecule deficiency in our patient, confirms the prominent role of these cells in curing such lesion. The therapeutic strategy of giving G-CSF beside transfusions was used to extend granulocytes half life. G-CSF was yet used in a child with acute lymphoblastic leukemia suffering from disseminated hyalohyphomycosis due to fusarium solani who developed an ecthyma gangrenosum-like lesion . This particular therapy supplies fresh normal granulocytes able to supplement drug effects. As granulogytes deficiency and/or inefficiency constitutes the primum movens of EG occurrence, granulocytes transfusions along with targeted drug therapy seems to be the best supportive mean to cure EG lesions, especially in severely immunocompromised patients.
For our patient, EG lesion was a result of a relatively unusual germ (fusarium solani) and extended over one year despite aggressive and specific therapy. Bacterial and fusarium solani persistence represented an aggravating element either by itself or by the massive antibiotic therapy used. Both intensive monitoring and targeted therapy probably with the overriding granulocytes transfusion role permitted EG healing.
An oral informed consent was obtained from the father of the patient for publication of this case report.
EG is a rare dermatologic infection due generally to bacteria and is commonly observed in patients with malignancy or neutropenia. Occurrence of such lesion secondary to fusarium solani in LAD I affected patient represents to our knowledge the first reported case. Granulocytes transfusions seem to be a good therapeutic option in such patient. This therapy can be generalized in severely immunocompromised patients affected by EG and/or in worst prognosis EG septicemic forms.
- Anderson DC, Springer TA: Leukocyte adhesion deficiency: An inherited defect in the Mac-1, LFA-1 and pp150, 95 glycoprotein. Annu Rev Med 1987, 38: 175–194. 10.1146/annurev.me.38.020187.001135View ArticlePubMedGoogle Scholar
- Reich HL, Williams Fadeyi D, Naik NS, Honiq PJ, Yan AC: Nonpseudomonal ecthyma gangrenosum. J Am Acad Dermatol 2004,50(Suppl 5):S114–17. 10.1016/j.jaad.2003.09.019View ArticlePubMedGoogle Scholar
- Khan F, Saul T: Ecthyma gangrenosum. J Emerg Med 2009.Google Scholar
- Gucluer H, Ergun T, Demircay Z: Ecthyma gangrenosum. Int J Dermatol 1999, 38: 299–02. 10.1046/j.1365-4362.1999.00691.xView ArticlePubMedGoogle Scholar
- Greene SL, Su WPD, Muller SA: Ecthyma gangrenosum: report of clinical, histopathologic and bacteriologic aspects of eight cases. J Am Acad Dermatol 1984, 11: 781–7. 10.1016/S0190-9622(84)80453-3View ArticlePubMedGoogle Scholar
- Rodot S, Lacour JP, Elslande L, Castanet J, Desruelles J, Ortonne JP: Ecthyma gangrenosum caused by Klebsiella pneumonia. Int J Dermatol 1995, 34: 216–7. 10.1111/j.1365-4362.1995.tb01575.xView ArticlePubMedGoogle Scholar
- Duman MO, Zdemir D, Yis U, Koroglu T, Oren O, Berktas S: Multiple erythematous nodules and ecthyma gangrenosum as a manifestation of Pseudomonas aeruginosa sepsis in a previously healthy infant. Pediatr Dermatol 2006, 23: 243–6. 10.1111/j.1525-1470.2006.00226.xView ArticlePubMedGoogle Scholar
- Boisseau AM, Sarlangue J, Perel Y, Hehunstre JP, Taieb A, Maleville J: Perineal ecthyma gangrenosum in infancy and early childhood; septicemic and non-septicemic forms. J Am Acad Dermatol 1992, 27: 415–8. 10.1016/0190-9622(92)70210-7View ArticlePubMedGoogle Scholar
- Weber DJ, Cohen MS, Rutala WA, Mandell : In Douglas and Bennett's principles and practice of infectious diseases: 2005; Philadelphia. Edited by: Mandell GL, Bennett JE, Dolin R. Elsevier; 2005:730–42.Google Scholar
- Fergie JE, Huang DB, Purcell K, Milligan T: Successful treatment of Fusarium solani ecthyma gangrenosum in a child with acute lymphoblastic leukemia in relapse. Pediatr Infect Dis J 2000, 19: 579–81. 10.1097/00006454-200006000-00022View ArticlePubMedGoogle Scholar
- Repiso T, García-Patos V, Martin N, Creus M, Bastida P, Castells A: Disseminated fusariosis. Pediatr Dermatol 13: 118–21. 10.1111/j.1525-1470.1996.tb01416.xGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-5945/10/10/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.